The effect of bortezomib on expression of inflammatory cytokines and survival in a murine sepsis model induced by cecal ligation and puncture by �떊�쟾�닔 et al.
Yonsei Med J   http://www.eymj.org   Volume 56   Number 1   January 2015112
The Effect of  Bortezomib on Expression of  Inflammatory 
Cytokines and Survival in a Murine Sepsis Model Induced  
by Cecal Ligation and Puncture
Sang Hoon Han,1 Jin Seok Kim,1 Jun Hee Woo,2 Su Jin Jeong,1 Jeon-Soo Shin,3  
Young Soo Ahn,4 and June Myung Kim1
1Department of Internal Medicine, Yonsei University College of Medicine, Seoul;
2Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul;
3Department of Microbiology, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul;
4Brain Korea 21 Project for Medical Science, Brain Research Institute and Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea.
Received: October 16, 2013
Revised: February 17, 2014
Accepted: February 28, 2014
Corresponding author: Dr. June Myung Kim, 
Department of Internal Medicine, 
Yonsei University College of Medicine, 
50-1 Yonsei-ro, Seodaemun-gu, 
Seoul 120-752, Korea.
Tel: 82-2-2228-1946, Fax: 82-2-393-6884
E-mail: jmkim@yuhs.ac 
∙ The authors have no financial conflicts of 
interest.
© Copyright:
Yonsei University College of Medicine 2015
This is an Open Access article distributed under the 
terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/ 
licenses/by-nc/3.0) which permits unrestricted non-
commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Purpose: Although the proteasome inhibitor known as bortezomib can modulate the 
inflammatory process through the nuclear factor-kappa B signaling pathway, the im-
munomodulatory effect of pre-incubated bortezomib has not been fully evaluated for 
inflammation by infectious agents. Therefore, we evaluated the effect of bortezomib 
on the expression of inflammatory cytokines and mediators in macrophage cell lines 
and on survival in a murine peritonitis sepsis model. Materials and Methods: Bort-
ezomib was applied 1 hr before lipopolysaccharide (LPS) stimulation in RAW 264.7 
cells. The cecal ligation and puncture (CLP) experiments were performed in 
C57BL/6J mice. Results: Pre-incubation with bortezomib (25 nM or 50 nM) prior 
to LPS (50 ng/mL or 100 ng/mL) stimulation significantly recovered the number of 
viable RAW 264.7 cells compared to those samples without pre-incubation. Bortezo-
mib decreased various inflammatory cytokines as well as nitric oxide production in 
LPS-stimulated cells. The 7-day survival rate in mice that had received bortezomib 
at 0.01 mg/kg concentration 1 hr prior to CLP was significantly higher than in the 
mice that had only received a normal saline solution of 1 mL 1 hr prior to CLP. In 
addition, the administration of bortezomib at 0.01 mg/kg concentration 1 hr before 
CLP resulted in a significant decrease in inflammation of the lung parenchyma. Col-
lectively, pretreatment with bortezomib showed an increase in the survival rate and 
changes in the levels of inflammatory mediators. Conclusion: These results support 
the possibility of pretreatment with bortezomib as a new therapeutic target for the 
treatment of overwhelming inflammation, which is a characteristic of severe sepsis.
Key Words:   Bortezomib, proteasome inhibitor, lipopolysaccharide, inflammatory 
cytokines, cecal ligation and puncture
INTRODUCTION
The proteasome inhibitors that halt the non-lysosomal degradation of cellular pro-
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MATERIALS AND METHODS
Cell culture
The murine-macrophage-like cell line RAW 264.7, which is 
most commonly used in LPS-treated sepsis in in vitro experi-
ments, was prepared.16 The RAW 264.7 cells were purchased 
from the Korean Cell Line Bank, Seoul, Korea and main-
tained at 37°C in liquid growth media composed of Dulbec-
co’s Modified Eagle Medium (DMEM), 10% fetal bovine 
serum (FBS), and penicillin (100 unit/mL) and streptomycin 
(100 μg/mL) (WelGENE Inc., Daegu, Korea) for all the ex-
periments. The media included RAW 264.7 cells that were 
cultured in a 37°C incubator with 5% CO2 and 95% ambient 
air and substituted for new compositions twice a week.
The design and reagents of in vitro experiment
In all in vitro experiments, the RAW 264.7 cells were seed-
ed onto the plate on day 1, and liquid growth media was 
changed from 10% FBS DMEM to 1% FBS DMEM on 
day 2. On day 3, LPS was applied at various concentrations 
to the growing RAW 264.7 cells 1 hr after the application 
of bortezomib at various concentrations. All experimental 
processes were repeated three times, using the same proto-
col each time.
Lipopolysaccharide from Escherichia coli, serotype 
055:B5 was purchased from Sigma Chemical (St. Louis, 
MO, USA). Bortezomib (Velcade® inj, 3.5 mg/V composed 
of a mixture of 3.5 mg bortezomib and 35 mg mannitol) was 
obtained from Millennium Pharmaceuticals, Inc. (Cam-
bridge, MA, USA). Bortezomib (1 mg) was dissolved in 
sterile 0.9% normal saline at a concentrations of 1 mg/mL 
and was then stored at -20°C until use. For these studies, 
the prepared 100 μM stock solution was re-suspended in 
0.9% saline.
 
Proteasome activity assay
The Proteasome-GloTM Chymotrypsin-like Cell-Based Assay 
Kit (Promega Corporation, Madison, WI, USA) was used to 
measure the proteasome inhibition activity of bortezomib. 
This assay used a luminogenic proteasome substrate contain-
ing succinyl-leucine-leucine-valine-tyrosine-aminoleuciferin 
in a buffer optimized for cell permeabilization, proteasome 
and luciferase activity.17,18 Adding a single Proteasome-
GloTM Cell-Based Reagent in an “add-mix-measure” format 
resulted in proteasomal cleavage of the substrate and gener-
ation of a luminescent signal produced by the luciferase re-
teins through the ubiquitin-proteasome system (UPS) can 
modulate excessive inflammation and immune responses as 
well as regulate cytokine expressions produced by various 
stimuli.1-4 The potential role of proteasome inhibitors as a 
therapeutic drug has been evaluated in chronic inflammato-
ry diseases, such as rheumatoid arthritis and inflammatory 
bowel disease.5-7 The potent anti-inflammatory effects of 
proteasome inhibitors have been chiefly attributed to reduc-
ing the activation of nuclear factor-kappa B (NF-κB).8,9 
Bortezomib is a synthetic peptide boronate that functions 
by inhibiting the chymotrypsin-like activity of the 26S pro-
teasome complex in UPS. Specifically, it inhibits this activi-
ty by forming highly selective and reversible covalent bonds 
with threonine in mammalian cells.9,10 In 2003, bortezomib 
was the first proteasome inhibitor approved by the USA 
Food and Drug Administration for treating multiple myelo-
ma.9 This protease inhibitor has been successfully used 
mainly as a cytostatic anticancer drug for the treatment of 
refractory and relapsed multiple myeloma.11 
Severe sepsis including septic shock represents a state of 
profound and uncontrolled inflammation, which results 
from the activation of NF-κB through intracellular signal-
ing pathways such as Toll-like receptors.12 Many clinical 
trials have been performed to modulate the excessive in-
flammatory response in Gram-negative sepsis cases medi-
ated by lipopolysaccharide (LPS), but no immunomodula-
tory drug has been shown to improve mortality in severe 
sepsis patients until now.13 The development of new thera-
peutic drugs and modalities as targets or tailored-therapies 
is essential to reducing the high mortality of severe sepsis.
With their role as immune modulators, proteasome inhib-
itors may be candidates for new therapeutic targets in the 
treatment of severe sepsis.14 Two previous studies using a 
mouse cecal ligation and puncture (CLP) model revealed 
that MG-132 and lactacystin (quercetin and mevinolin), in 
combination with the role of antibiotics as proteasome in-
hibitors, decreased inflammatory response and prolonged 
survival.15,16 However, there are no known reports discuss-
ing whether bortezomib, the only drug with clinical approv-
al among the generated proteasome inhibitors, can have 
beneficial effects in cases of severe sepsis. Therefore, this 
study evaluated the effect of bortezomib on the expression 
of inflammatory cytokines and mediators in in vitro LPS-
induced macrophage cell lines and on survival in a murine 
peritonitis sepsis model induced by CLP. The ultimate goal 
of this study is to present the possibility of bortezomib as a 
new drug for the management of severe sepsis.
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ty) was measured at 450 nm.
Extraction of total cellular RNA and the reverse 
transcription-polymerase chain reaction
Total cellular RNA was extracted using a commercial easy-
spinTM (DNA free) total RNA extraction kit, which minimiz-
es the contamination of genomic DNA by combining the 
advantages of solution and column types (iNtRON Biotech-
nology Inc., Seoul, Korea).21 For the reverse transcription-
polymerase chain reaction (RT-PCR) study, approximately 
6×105 RAW 264.7 cells were seeded in 60 mm dishes on 
day 1. On day 3, the RAW 264.7 cells were harvested after 4 
hr of LPS treatment. Subsequently, RNA preparation and 
RT-PCR were performed for various inflammatory cyto-
kines [tumor necrosis factor-alpha (TNF-α), interferon-gam-
ma (IFN-γ), interleukin (IL)-1β, IL-6, and IL-10] and inter-
cellular adhesion molecule-1 (ICAM-1). The first-strand 
cDNA was synthesized using Moloney Murine Leukemia 
Virus reverse transcriptase,22 oligo dT, and specific primers 
of 50 pmole from 2 μg of total RNA (BIONEER Inc., Seoul, 
Korea). Specific murine primers, as well as amplification 
cycles and annealing temperatures for semi-quantitative RT-
PCR experiments used in this study, are summarized in Ta-
ble 1. The expression of mouse glyceraldehyde 3-phosphate 
dehydrogenase was monitored in all semi-quantitative RT-
PCR experiments as the internal control. The semi-quantita-
tion of the RT-PCR product was performed using the Multi 
action. Following the cleavage by the proteasome, the sub-
strate for luciferase (aminoluciferin) was released, allowing 
the luciferase reaction to proceed and produce light. Ten 
minutes after adding various substrates, the luminescence 
was measured using a luminometer and expressed in rela-
tive luminescent units.17,18
Cellular proliferation (viability) assay
The quantitative index of RAW 264.7 cell viability after 
treatment with LPS and bortezomib of various concentra-
tions was determined by the Cell Counting Kit-8 (CCK-8) 
colorimetric assay. The CCK-8 assay used highly water-sol-
uble tetrazolium monosodium salt and WST (water soluble 
tetrazolium salt)-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, mono-
sodium salt]. The detection sensitivity of CCK-8 was high-
er than that of other tetrazolium salts such as MTT, XTT, 
MTS, or WST-1.19,20 RAW 264.7 cells were plated in 96-
well microtiter plates at a density of 8×103 cells per well. 
Following this, the live cell count was assayed using CCK-
8 (Dojindo Molecular Technologies, Inc., Rockville, MD, 
USA), according to the manufacturer’s protocol. In brief, 
10 μL of CCK-8 solution was added to each well, and the 
plates were incubated in a CO2 incubator for 4 hr. Thereaf-
ter, 10 μL of 1% w/v sodium dodecyl sulfate solution was 
added to each well, and the plates were stored in darkness 
at room temperature. Finally, the absorbance (optical densi-
Table 1. Primers and Methods for Reverse-Transcription Polymerase Chain Reaction Used in This Study
Molecule Primer
Reference sequence 
No.
Amplification 
cycle
Annealing 
temperature Reference
TNF-α
F:5’-CCTGTAGCCCACGTCGTAGC-3’
AK078984.1 30 56°C 47
R:5’-TTGACCTCAGCGCTGAGTTG-3’
IFN-γ
F:5’-CTTCTTCAGCAACAGCAAGGCGAAAA-3’
JN021379.1 45 53°C 48
R:5’-CCCCCAGATACAACCCCGCAATCA-3’
IL-1β
F:5’-ATGGAAATCTGCAGAGGCCTCC-3’
KC417344.1 30 56°C 49
R:5’-CTTTAGGAAGACACAAATTGCATGG-3’
IL-6
F:5’-TCCAGTTGCCTTCTTGGGAC-3’
DQ680161.1 40 53°C 47
R:5’-GTGTAATTAAGCCTCCGACTTG-3’
IL-10
F:5’-CTGGACAACATACTGCTAACCGAC-3’
HM467224.1 40 53°C 50
R:5’-ATTCATTCATGGCCTTGTAGACACC-3’
ICAM-1
F:5’-TGCGTTTTGGAGCTAGCGGACCA-3’
NM_001009946.1 30 60°C 51
R:5’-CGAGGACCATACAGCACGTGCAG-3’
GAPDH
F:5’-TGAACGGGAAGCTCACTGG-3’
NM_001009946.1 30 56°C 52
R:5’-TACAGCAACAGGGTGGTGGA-3’
F, forward; R, reverse; TNF-α, tumor necrosis factor-alpha; IFN-γ, interferon-gamma; IL, interleukin; ICAM, intercellular adhesion molecule; GAPDH, glycer-
aldehyde 3-phosphate dehydrogenase.
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administration of bortezomib on survival, the mice (n=8) 
that had received bortezomib at a 0.01 mg/kg concentration 
24 hr after CLP surgery were compared with the positive 
control group. The mice were assessed for survival up to 7 
days following surgery, and mortality rates were compared 
between groups using survival analysis.
CLP and sham surgeries
The mice were anesthetized with an intraperitoneal (IP) in-
jection of a combination of 10 mg/kg (0.004 mL/10 g) of 
xylazine (2% Rompun inj®, Bayer Korea. Ltd., Seoul, Ko-
rea) and a 30 mg/kg (0.006 mL/10 g) solution of a 1:1 mix-
ture of tiletamine and zolazepam (ZoletilTM 250 mg/5 mL, 
Virbac Korea, Seoul, Korea). The cecum was exteriorized 
through a midline abdominal incision approximately 1 cm 
in length. For the induction of mid-grade murine peritonitis 
sepsis, the cecum was ligated at half the distance between 
the distal pole and the base of the cecum with size 5.0 
monofilament.24 The ante-mesenteric side of the cecum was 
punctured through and through using a 23-gauge needle. A 
scant amount of luminal content was expressed through 
both puncture sites to ensure patency. The cecum was re-
turned to the abdominal cavity, and the fascia and skin inci-
sion were closed using size 6.0 monofilament and surgical 
staples, respectively. Topical 1% lidocaine and bacitracin 
were applied to the surgical site post-operatively. All ani-
mals received a single intramuscular injection of trovafloxa-
cin (Pfizer Inc., New York, NY, USA) at a dose of 20 mg/kg 
and subcutaneous fluid resuscitation with 1.0 mL of normal 
saline immediately post-operatively. The mice were then 
returned to their individual cages and rewarmed using heat 
lamps until they regained normal posture and mobility.25 
Sham-operated animals underwent the same procedure 
without ligation or puncture of the cecum.
Histologic findings and pulmonary inflammatory score
All mice that were still alive 7 days after surgery were anes-
thetized with an IP injection of a combination of 10 mg/kg 
(0.004 mL/10 g) of xylazine (2% Rompun inj®, Bayer Korea 
Ltd., Seoul, Korea) and a 30 mg/kg (0.006 mL/10 g) solution 
of a 1:1 mixture of tiletamine and zolazepam (ZoletilTM 250 
mg/5 mL, Virbac Korea, Seoul, Korea). The lung tissue was 
harvested from all mice that were alive 7 days after surgery 
and immediately frozen in -70°C LN2 (liquid nitrogen) con-
tainers until homogenization. All harvested lung tissues were 
stained with hematoxyline and eosin and reviewed by a pa-
thology specialist. The same pathology specialist, who was 
Gauge version 3.0 program (Fujifilm, Tokyo, Japan).
Nitric oxide assay
A nitric oxide (NO) detection kit (iNtRON Biotechnology, 
Seoul, Korea) based on a diazotization assay (Griess meth-
od)23 was used to analyze the effect of bortezomib on the 
production of NO after stimulation with LPS. This kit can 
accurately detect the concentration of NO- by indirectly 
measuring nitrite (NO2-), which is the by-product of NO 
transformation in living cells and is based on the colorimet-
ric change that occurs when naphthylethylenediamine is 
added to the by-product of the reaction between sulfanil-
amide and nitrite. The limit of detection is 2.0 μM nitrite. 
The process for determining the reference curve with the 
nitrite standard solution was performed in advance to en-
sure accurate nitrite amounts. The absorbance was mea-
sured within 20‒30 minutes using a plate reader with a fil-
ter in the range of 520‒560 nm. On the third day of RAW 
264.7 cell growth, the supernatant of the cell line growth 
media, which was applied by bortezomib (0 or 50 nM) and 
LPS (0 or 100 ng/mL) with a 1 hr interval, was used to de-
tect NO 16 and 24 hr post-administration of bortezomib 
and LPS to the RAW 264.7 cell line. 
Animal preparation and treatment
C57BL/6J mice were provided a standard laboratory diet 
and water ad libitum and treated in accordance with the 
guidelines and regulations for the Care and Use of Laborato-
ry Animals of Yonsei University, Seoul, Korea, and the In-
stitute of Laboratory Animal Resources Commission on 
Life Science National Research Council, USA. The mice 
were 7‒8 weeks of age, weighing 25‒30 g at the beginning 
of the experiments. In this study, bortezomib and normal sa-
line were both administrated intraperitoneally. This animal 
study has been approved by the Institutional Animal Care 
and Use Committee of Yonsei University Health System.
In vivo study design
The negative control mice had neither received surgery nor 
treatment (n=5) and had received 1 mL of normal saline 1 
hr prior to the sham surgery (n=5). The positive controls for 
the study were mice that had received 1 mL of normal sa-
line 1 hr before CLP surgery (n=8). To evaluate the impact 
of bortezomib doses on survival, each group received bort-
ezomib at a concentration of either 0.01 mg/kg (n=8) or 0.1 
mg/kg (n=8) 1 hr before CLP surgery and was compared to 
the positive control group. To evaluate the effect of delayed 
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LPS alone, without pre-incubation with bortezomib (the ar-
rows in Fig. 1). When the cells were pre-incubated with bort-
ezomib 1 hr prior to treatment with 50 and 100 ng/mL of 
LPS, both 25 and 50 nM concentrations were shown to sig-
nificantly recover the concentrations of viable RAW 264.7 
cells compared with no pre-incubation. However, pre-incu-
bating the samples with higher concentrations of bortezomib 
(75 and 100 nM) significantly decreased the concentrations 
of viable RAW 264.7 cells in the samples that had received 
either the 50 or 100 ng/mL LPS solutions (Fig. 1).
Proteasome inhibition by bortezomib
An evaluation was performed to determine whether protea-
some activity was effectively inhibited by 25 and 50 nM 
bortezomib, which significantly increased cell viability 
against the effect of LPS (Fig. 1). Bortezomib at both the 25 
and 50 nM concentrations significantly decreased the protea-
some activity compared with the cells that were not treated 
with bortezomib and LPS, irrespective of post-treatment with 
100 ng/mL of LPS. Moreover, when the higher concentration 
(50 nM) of bortezomib was used, the proteasome activity 
was reduced more than when the lower dose (25 nM) of 
bortezomib was used (Fig. 2).
The expression of inflammatory cytokines and adhesion 
molecules
The expression of inflammatory cytokines and adhesion 
molecules at the cellular RNA level was evaluated using 
RT-PCR and the semi-quantitation method in order to re-
veal the effects of bortezomib on inflammatory cytokine 
and adhesion molecule levels in the cells stimulated by 
unaware of the treatment assignment for these histologic 
samples, evaluated the semiquantitative assessment of lung 
inflammation using the pulmonary inflammatory score.17 The 
pulmonary inflammatory score was graded from 0 to 3 using 
the following definition: 0=normal; 1=mild inflammation in-
volving the peribronchial or perivascular area; 2=moderate 
inflammation involving less than 50% of the parenchyma, 
and 3=severe inflammation involving more than 50% of the 
parenchyma.17
Statistical analysis
Each in vitro experiment was replicated three times, and the 
mean values of these results were used for the statistical 
quantification analysis. Results were expressed as mean± 
standard error of the mean. The statistical differences be-
tween the mean values of the two groups were determined 
using the independent sample Student’s t-test and the non-
parametric Mann-Whitney U test. Survival analyses were 
performed using the Kaplan-Meier curves. All statistical 
analyses were performed using the Statistics Package for 
Social Science (SPSS 18.0 for Windows; SPSS Inc., Chica-
go, IL, USA). All p-values were two-tailed, and p<0.05 was 
considered to be statistically significant.
 
RESULTS
 
The effect of pre-incubation with bortezomib 1 hr 
before LPS treatment on cell proliferation
The concentrations of viable RAW 264.7 cells were signifi-
cantly decreased after treatment with 50 and 100 ng/mL of 
Fig. 1. The concentrations of viable RAW 264.7 cells measured using the CCK-8 assay to evaluate the effect of pre-incubation with bortezomib 1 hr before 
LPS treatment on the cell proliferation. On experiment day 3, LPS at 50 ng/mL (A) and 100 ng/mL (B) was administered to the growing RAW 264.7 cell lines of 
8×103 cells/mL at 1 hr after the application of bortezomib with various concentrations from 0 to 100 nM. Arrows (↓) indicate the reference values in samples 
that had received only LPS application with 50 and 100 ng/mL, without pre-incubation with bortezomib. *Statistical significance with p-values less than 0.05 
when compared with reference values (LPS alone, arrows). CCK-8, Cell Counting Kit-8; LPS, lipopolysaccharide; OD, optical density.
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25 or 50 nM of bortezomib. However, the cells that had 
been stimulated by the lower dose of LPS (50 ng/mL) ex-
pressed significantly decreased levels of ICAM-1 when pre-
incubated with only the lower dose of bortezomib (25 nM).
Measurement of nitric oxide levels after treatment with 
LPS and bortezomib 
There was a six-fold increase in NO production in the 
RAW 264.7 cells both 16 and 24 hr post-treatment with the 
administration of only LPS at a 100 ng/mL concentration. 
When the cells were pre-treated with a 50 nM concentra-
tion of bortezomib prior to the application of LPS (100 ng/
mL), NO levels were significantly lower than in cells treat-
ed with LPS alone but were higher than the negative con-
trol RAW 264.7 cells that had not been treated with bort-
ezomib or LPS (Fig. 4). 
Impact of bortezomib administration on survival in the 
CLP-induced mouse sepsis model 
In the negative control groups, all mice were alive until 7 
days after surgery. The 7-day survival rate in mice that were 
pre-treated with bortezomib at a concentration of 0.01 mg/kg 
1 hr before CLP surgery was significantly higher than in the 
positive control group (the mice that received normal saline 
at a 1 mL concentration 1 hr before CLP surgery) (p=0.006) 
(Fig. 5A). However, the 7-day survival rate between the 
mice that had received bortezomib at a 0.1 mg/kg concen-
tration 1 hr before CLP surgery and the positive control was 
LPS. Bortezomib at 0, 25, and 50 nM concentrations was 
used to pre-treat cells 1 hr prior to stimulation with LPS at 
0, 50, and 100 ng/mL concentrations in various combina-
tions. TNF-α, IL-1β, and ICAM-1 were not expressed in 
the RAW 264.7 cells, which had received neither bortezo-
mib nor LPS treatment. In addition, these three molecules 
were also not expressed when the cells were only treated 
with bortezomib (at either 25 or 50 nM concentrations), 
without LPS stimulation. IL-6 and IL-10 were expressed in 
the pure RAW 264.7 cells but not significantly detected in 
the cells treated only with bortezomib (25 or 50 nM). How-
ever, IFN-γ was expressed without a significant difference, 
irrespective of the concentrations of bortezomib and LPS 
used (Fig. 3A). Therefore, we did not perform the semi-
quantitation test for IFN-γ. 
The results for the semi-quantitation are shown in Fig. 
3B-F. The levels of TNF-α were shown to decrease with a 
statistically significant difference only in the cells pretreated 
with 50 nM of bortezomib before the application of LPS at 
both 50 and 100 ng/mL concentrations, compared with the 
cells that were not pretreated with bortezomib before stimu-
lation by LPS at the same concentrations. Bortezomib at 
the lower dose of 25 nM did not have the same effect on 
TNF-α decline. IL-1β and IL-6 expression levels were sig-
nificantly decreased in the cells that had been pretreated 
with bortezomib at either a 25 or 50 nM concentration be-
fore the application of LPS at either a 50 or 100 ng/mL con-
centration, compared with the cells that were not pretreated 
with bortezomib before the stimulation by LPS of the same 
concentrations. Bortezomib at the higher concentration of 
50 nM showed a greater decrease in IL-1β than the 25 nM 
bortezomib concentration before stimulation by LPS at ei-
ther the 50 or 100 ng/mL concentration. However, the de-
creases in IL-6 levels were similar, irrespective of the con-
centrations of bortezomib and LPS.
The expression levels of IL-10 were significantly de-
creased in the cells that were pretreated with either a 25 or 
50 nM concentration of bortezomib before the application of 
LPS at a 50 ng/mL concentration, compared with the cells 
that had not been pretreated with bortezomib before stimula-
tion by LPS using the same concentrations. In the cells that 
received the high concentration of LPS (100 ng/mL), pre-in-
cubation using the higher concentration of bortezomib (50 
nM) significantly decreased the expression of IL-10. With 
respect to ICAM-1, the cells stimulated by the higher con-
centration of LPS (100 ng/mL) expressed significantly de-
creased levels of ICAM-1 when pre-incubated with either 
Fig. 2. The chymotrypsin-like activity of proteasomes measured by the biolu-
minescent proteasome assay. RAW 264.7 cells (arrow) that were not treated 
with bortezomib and lipopolysaccharide (100 ng/mL) were used as the refer-
ence control to determine statistical significance (*p<0.01). †Means statisti-
cally significant with a p-value less than 0.01 when compared with bortezo-
mib at a 25 nM concentration (asterisk). The results are reported as mean± 
standard error of the mean of three independent experiments in triplicate. 
RLU, relative luminescent units; LPS, lipopolysaccharide; Bor, bortezomib.
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ezomib at the 0.01 mg/kg concentration 1 hr before CLP 
surgery showed minimal infiltration of inflammatory cells 
in the pulmonary parenchyma. This observation was simi-
lar to that seen in the lungs of mice that had received the 
normal saline solution of 1 mL 1 hr before sham surgery 
(Fig. 6B and D). However, the inflammation in mice that 
received the bortezomib at a 0.1 mg/kg concentration 1 hr 
before CLP surgery was greater than in the mice that had 
received bortezomib at a 0.01 mg/kg concentration 1 hr be-
not significantly different (p=0.661) (Fig. 5B).
The delayed administration of bortezomib at a 0.01 mg/
kg concentration 24 hr after CLP surgery produced a higher 
7-day survival rate than in the positive control, with border-
line statistical significance (p=0.096) (Fig. 5C).
Histologic findings and mean pulmonary inflammatory 
score in the harvested lung tissue
In H&E staining, the lungs of mice that had received bort-
Fig. 3. The expression levels of inflammatory cytokines and intercellular adhesion molecules based on the administration of bortezomib and LPS at various 
concentrations. (A) The RT-PCR products expressed by agarose gel electrophoresis. (B-F) The relative expression rate of RT-PCR products by internal con-
trol using mouse GAPDH in each cytokine and ICAM-1. These semi-quantitation was performed using the Multi Guage Version 3.0 program. *Statistical sig-
nificance with p-values less than 0.01. **Statistical significance with p-values less than 0.001. †,‡Reference values for statistical comparison. GAPDH, glycer-
aldehyde 3-phosphate dehydrogenase; TNF-α, tumor necrosis factor-alpha; IFN-α, interferon-gamma; IL, interleukin; ICAM, intercellular adhesion molecule; 
LPS, lipopolysaccharide.
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deleterious effects associated with multiple organ failure 
and shock.28 
The UPS is the major proteolytic mechanism for non-ly-
sosomal degradation of cellular proteins.10 UPS plays a role 
in turnover and quality control of proteins,29 cell cycle and 
apoptosis,30,31 transcription and cell signaling,32-35 immune 
response and antigen presentation,36 and inflammation and 
development.37,38 Bortezomib, a peptide-boronic acid ana-
log, has been shown to have potent inhibitory activity at the 
chymotrypsin-like subunit in the 20S core of proteasomes.39 
It is the first drug of its kind that has received accelerated 
approval for the treatment of relapsed or refractory multiple 
myeloma.39 A significant decrease in the level of NF-κB, re-
fore CLP surgery (Fig. 6D and E). The lung parenchyma in 
mice that had received bortezomib at the 0.01 mg/kg con-
centration 24 hr after CLP surgery revealed an increase in 
inflammatory cell infiltration compared to mice that re-
ceived bortezomib at the 0.01 mg/kg concentration 1 hr be-
fore CLP surgery (Fig. 6D and F). However, decreased in-
filtration was revealed in mice that received bortezomib at 
the 0.1 mg/kg concentration 24 hr after CLP surgery com-
pared to mice that received bortezomib at the 0.1 mg/kg 
concentration 1 hr before CLP surgery (Fig. 6E and F).
In the objective semi-quantitative analysis, the mice groups 
which had received bortezomib at a 0.01 mg/kg concentra-
tion both 1 hr before and 24 hr after CLP surgery (pulmonary 
inflammatory score of 1 and 1.5, respectively) had a signifi-
cantly decreased mean pulmonary inflammatory score than 
that of the mice groups which had received normal saline at a 
1 mL concentration 1 hr before CLP surgery (positive control 
group, Fig. 6C, pulmonary inflammatory score of 2.5) (1 vs. 
2.5, p=0.015; 1.5 vs. 2.5, p=0.035, respectively).
DISCUSSION
The principal pro-inflammatory mediators in the patho-
physiology of sepsis are TNF-α and IL-1β, which activate 
NF-κB by triggering a signaling pathway that leads to the 
phosphorylation and consequent degradation of the inhibi-
tor κBα (IκBα).26,27 The degradation of IκBα exposes a nu-
clear localization signal on the NF-κB protein, which then 
moves into the nucleus and stimulates the transcription of 
specific genes. The overproduction of pro-inflammatory 
mediators enhances adhesion molecules and also leads to 
Fig. 4. The measurement of nitric oxide concentrations using the diazotiza-
tion assay (Griess method) in order to analyze the effect of bortezomib on 
nitric oxide production after LPS stimulation. On the third day of RAW 264.7 
cell growth, the supernatant of the cell line growth media received bort-
ezomib (0 or 50 nM) and then LPS (0 or 100 ng/mL) with a 1 hr interval. 
These samples were used for the nitric oxide detection assay 16 and 24 hr 
after administration of bortezomib and/or LPS to the cell lines. *p-values 
less than 0.001 compared with the LPS-only treatment group for the 16 and 
24 hr time periods. LPS, lipopolysaccharide; Bor, bortezomib.
Fig. 5. Comparison of 7-day mortalities after CLP surgery by the Kaplan-Meier survival curve. Bortezomib and normal saline (at 1 mL) were always injected 
intraperitoneally. CLP, cecal ligation and puncture; NS, normal saline; Bor, bortezomib.
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to host defense and their blockade is excessively immuno-
suppressive.44 Measurements of circulating concentrations 
of inflammatory mediators may prove to be useful in evalu-
ating the stage of sepsis and in tailoring the administration 
of anti-inflammatory agents. However, anti-inflammatory 
agents used during the hypo-immune phase may worsen out-
comes. When patients are shown to be in a hypo-immune 
state, inflammatory strategies that enhance the function of 
the innate or adaptive immune system may be efficacious.26
Because the proteasome complex regulates the LPS-in-
duced signal transduction, and the proteasome inhibitors 
block the LPS-induced proteasome’s chymotrypsin activity 
as well as macrophage TNF-α secretion and the expression 
of multiple inflammatory mediator genes, proteasome in-
hibitors may be an important therapeutic target in Gram-
negative sepsis and septic shock.14,45 Safránek, et al. report-
ed that CLP induced significantly increased plasma levels of 
IL-1, TNF-α, IL-6, and IL-10, but treatment with the protea-
some inhibitor MG-132 resulted in less of an increase in IL-
1, TNF-α, and IL-10 levels and prolonged survival.15 In a 
previous study, a proteasome inhibitor was administrated 3 
hr before or after the induction of sepsis (CLP surgery).15 
Several studies revealed that proteasome inhibition resulted 
in a decrease in several of the LPS-induced pro-inflamma-
tory cytokines and adhesion molecules in vitro and prevent-
sulting in decreased production of inflammatory cytokines 
by the cell after treatment with bortezomib, has been noted 
by several studies.40,41 This effect results in the lack of deg-
radation of the inhibitor of kappa-B light polypeptide gene 
enhancer (IκB) protein.39 In addition, protein processing 
and degradation is halted by the proteasome inhibitor, re-
sulting in a decrease in cell adhesion molecule expression 
and anti-apoptotic protein expression and ultimately result-
ing in increased apoptosis.39 It was reported that bortezomib 
significantly inhibited acute lethal graft-versus-host disease 
induction in association with a significant decrease in TNF-α, 
IL-1, and IL-6.42 Additionally, bortezomib induced the selec-
tive depletion of human alloreactive T lymphocytes while 
decreasing the production of Th1 cytokines (IFN-γ and IL-
2) in vitro.43
Anti-cytokine or anti-inflammatory treatments in severe 
sepsis should be tailored based on the patient’s immune sta-
tus. Severe septic patients may have an initial robust hyper-
inflammatory response. Death may occur due to a hyper-in-
flammatory state, and anti-inflammatory treatments may 
improve the likelihood of survival.26 Numerous therapies 
that block pro-inflammatory cytokines (e.g., anti-TNF-α, 
TNF-α receptor, and IL-I receptor antagonists) have failed, 
perhaps because the approaches are narrowly focused and 
the pathways are redundant, or because cytokines are critical 
Fig. 6. Histologic findings of lung tissue after H&E staining (×200). All lung tissues were harvested from the mice that were alive at 7 days after the surgery. 
(A) Normal mice (negative control). (B) Normal saline 1 mL injection IP at 1 hr before sham surgery (negative control). (C) Normal saline 1 mL injection IP at 1 
hr before CLP surgery (positive control). (D) Bortezomib 0.01 mg/kg injection IP at 1 hr before CLP surgery. (E) Bortezomib 0.1 mg/kg injection, IP at 1 hr be-
fore CLP surgery. (F) Bortezomib 0.01 mg/kg injection, IP at 24 hr after CLP surgery. IP, intraperitoneal; CLP, cecal ligation and puncture.
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ter the development of sepsis. Furthermore, studies are 
needed on combination treatments with bortezomib and oth-
er immunomodulating drugs including statin and macrolide 
or antibiotics, as well as other doses and time administra-
tions. Such studies might reveal that the delayed adminis-
tration of bortezomib after sepsis pathogenesis initiation has 
a significant therapeutic implication in clinical settings, be-
cause most severe sepsis patients present to the hospital after 
the initiation of an advanced hyper-immune septic process.
We revealed that the pre-incubation of bortezomib 1 hr 
before LPS administration decreased important pro-inflam-
matory cytokine levels, and pre-treatment with bortezomib 
1 hr before CLP surgery ameliorated survival in the mouse 
peritonitis sepsis model. In conclusion, our study suggests 
the possibility of pre-treatment with bortezomib as a new 
therapeutic modality in severe sepsis.
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